Treatments, Patient Characteristics Affect Uveal Melanoma Survival

Source: CureToday, July 2023

A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.

Patients with metastatic uveal melanoma (UM) experienced improved survival outcomes if treated with immune checkpoint inhibitors (ICIs, a type of immunotherapy that assists the immune system find and fight cancer), including anti-CTLA-4 and anti-PD-1 therapies, according to the findings of a new study.

Factors such as female sex, extrahepatic-only metastases (secondary malignant growths not in the liver), better baseline performance status on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale, laboratory measurements and metastasis location all “contributed to a more than 2-fold reduction in death risk,” according to the authors of the study, published in the journal Cancer.